Mupirocin

Blog · Antibiotic

Mupirocin

Nature

  • Fermentation product of Pseudomonas fluorescence.

Mechanism of action

  • Mupirocin inhibits bacterial protein synthesis by binding reversibly to the bacterial isoleucyl transfer-RNA synthetase enzyme. This mechanism is unique; hence, no cross-resistance with other antibiotics has been reported.
    It prevents bacterial protein synthesis.

Mechanism of resistance

  • Low-level resistance (MIC 8-256) – Low-level resistance is chromosomal; it is due to point mutation in ileS gene. This gene codes for isoleucyl tRNA synthetase.
  • High-level resistance (MIC>512) – Plasmid;  mupA gene mediated – which generates additional isoleucyl tRNA transferase.
  • The risk of resistance is higher in cases of – long-term use, use in the presence of a foreign body (NG tube), and decubitus ulcer.

 PK/PD

  • Inactivated in plasma, and hence it is only used topically.
  • Bacteriostatic near MIC and bactericidal at higher concentrations.
  • Poorly absorbed when used topically, absorbed drugs get metabolised in the liver.

Spectrum

  • Staph aureus (including MRSA, VISA, VRSA), strep, CoNS, Enterococci, and Streptococcus bovis have high MIC,
  • Micrococcus resistant. Corynebacterium and anaerobic gram positives are resistant.
  • Haemophilus, Moraxella, Neisseria, Bordetella, Pasteurella sensitive.

Adverse effect

  • Burning, stinging, itching, rash, headache.
  • Mupirocin prep containing polyethylene glycol should be used with caution in renal impairment.

Use

  • Eradication regimen for MRSA – anterior nares BD X 5 days. [Cochrane review 2008]
  • NOT indicated for the prophylaxis of clean surgical wounds.
Disclaimer: This is for academic use only. Managing an infection is complex and depends on taking multiple factors into account. Please speak to your doctor for clinical advice. This article must never be used for clinical purposes.
Scroll to Top